Patoloxía Molecular das Doenzas Raras
PatMol-DR
![Foto de Patoloxía Molecular das Doenzas Raras](/img/grupo.png)
![Foto de National and Kapodistrian University of Athens](/img/noimage_org.png)
National and Kapodistrian University of Athens
Atenas, GreciaPublicacións en colaboración con investigadores/as de National and Kapodistrian University of Athens (4)
2023
-
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955
2022
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392